Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Teva Pharma to settle...

    Teva Pharma to settle $85 million opioid claims of Oklahoma

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-27T09:00:27+05:30  |  Updated On 16 Aug 2021 2:44 PM IST

    Oklahoma Attorney General Mike Hunter has alleged that JnJ and Teva Pharma, along with OxyContin maker Purdue Pharma LP, carried out deceptive marking campaigns that downplayed opioids' addictive risks while overstating their benefits.


    BOSTON: Teva Pharmaceutical Industries said on Sunday it had agreed an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped to fuel the U.S. opioid epidemic.


    Teva, the world's largest generic drugmaker, said the settlement "does not establish any wrongdoing on the part of the company" and denied contributing to opioid abuse in Oklahoma.


    Read Also: US states sue 20 drug firms including Teva Pharma over pricing cartel


    Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced.


    The trial against Israel-based Teva, along with Johnson & Johnson, was set to begin on Tuesday. The lawsuit alleged the companies' marketing of the painkiller was to blame for the opioid epidemic.


    Johnson & Johnson had no immediate comment.


    Oklahoma Attorney General Mike Hunter has alleged that J&J and Teva, along with OxyContin maker Purdue Pharma LP, carried out deceptive marking campaigns that downplayed opioids' addictive risks while overstating their benefits.


    The state also alleges the companies' actions created an oversupply of painkillers and a public nuisance that will cost $12.7 billion to $17.5 billion to remedy.


    Read Also: USFDA nod to Teva generic nasal spray-Narcan to treat opioid overdose


    Oklahoma resolved its claims against Purdue Pharma LP in March for $270 million.


    The Oklahoma case is being closely watched by plaintiffs in other opioid cases, particularly some 1,850 mostly municipal and state governments that have sued the same drugmakers in the federal court in Ohio.


    "Teva is pleased to put the Oklahoma case behind it and remains prepared to vigorously defend claims against the company, including the upcoming federal court trial in Cleveland where the majority of the cases are pending," the company said.


    Attorney General Hunter's office said in a statement the money would be used to address the opioid crisis in Oklahoma and that the J&J case is still scheduled to go to trial on Tuesday before Cleveland County District Judge Thad Balkman.


    "Nearly all Oklahomans have been negatively impacted by this deadly crisis and we look forward to Tuesday, where we will prove our case against Johnson & Johnson and its subsidiaries," Hunter said in a statement.

    generic painkillersJnJJohnson & JohnsonMike HunterOklahomaOklahoma Attorneyopioidopioid abuseopioid claimsopioid epidemicOxyContinpainkillerplaintiffsPurdue PharmaTeva PharmaTeva Pharmaceutical
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok